Pyxis Oncology, Inc. (PYXS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PYXS
- Company Pyxis Oncology, Inc.
- Price $2.77
- Changes Percentage 24.22
- Change 0.54
- Day Low $2.2
- Day High $3
- Year High $5.55
- Year Low $0.97
- Market Cap $107,704,316
- Price Avg 50 EMA (D) $1.8
- Price Avg 200 EMA (D) $2.27
- Exchange NASDAQ
- Volume 178,748
- Average Volume 497,214
- Open $2.24
- Previous Close $2.23
- EPS -1.3
- PE -1.31
- Earnings Announcement 2026-08-13 04:00:00
- Shares Outstanding $63,355,480
Company brief: PYXIS ONCOLOGY, INC. (PYXS )
- Healthcare
- Biotechnology
- Dr. Lara S. Sullivan M.D., MBA
- https://www.pyxisoncology.com
- US
- N/A
- 10-08-2021
- US7473241013
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.